MWC
ALXN

MBM Wealth Consultants’s Alexion Pharmaceuticals ALXN Stock Holding History

MBM Wealth Consultants’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,916
Closed -$535K – 302
2021
Q2 		$535K Buy
2,916
+57
+2% +$9.78K 0.25% 50
2021
Q1 		$437K Buy
2,859
+121
+4% +$18.7K 0.22% 56
2020
Q4 		$428K Sell
2,738
-183
-6% -$23.5K 0.23% 51
2020
Q3 		$335K Buy
2,921
+263
+10% +$28.4K 0.21% 60
2020
Q2 		$299K Sell
2,658
-1,041
-28% -$111K 0.21% 63
2020
Q1 		$332K Buy
3,699
+421
+13% +$41.3K 0.27% 63
2019
Q4 		$354K Buy
3,278
+241
+8% +$25.8K 0.26% 71
2019
Q3 		$297K Buy
3,037
+208
+7% +$23.4K 0.23% 75
2019
Q2 		$372K Buy
2,829
+167
+6% +$21.5K 0.31% 72
2019
Q1 		$360K Buy
2,662
+201
+8% +$25K 0.32% 70
2018
Q4 		$240K Buy
+2,461
New +$291K 0.23% 81

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

MBM Wealth Consultants's ALXN Position: Q3 2021 in Review

MBM Wealth Consultants sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 2,916 shares — an estimated $535K sold.

MBM Wealth Consultants first reported a position in ALXN in Q4 2018 and held it in 11 quarters. The position peaked at $535K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • MBM Wealth Consultants reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • MBM Wealth Consultants sold 2,916 Alexion Pharmaceuticals shares in Q3 2021, an estimated $535K.
  • MBM Wealth Consultants first reported a position in Alexion Pharmaceuticals in Q4 2018 and held it in 11 quarters.
  • MBM Wealth Consultants's Alexion Pharmaceuticals position peaked at $535K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on MBM Wealth Consultants's 13F filing for Q3 2021, filed 16 Nov 2021.